Phase I pilot study of Wilms tumor gene 1 peptide-pulsed dendritic cell vaccination combined with gemcitabine in pancreatic cancer

Cancer Science

Volumn 106, Issue 4, 2015, Pages 397-406

  Mayanagi, Shuhei ^a   Kitago, Minoru ^a   Sakurai, Toshiharu ^a   Matsuda, Tatsuo ^a   Fujita, Tomonobu ^a   Higuchi, Hajime ^b   Taguchi, Junichi ^c   Takeuchi, Hiroya ^a   Itano, Osamu ^a   Aiura, Koichi ^d   Hamamoto, Yasuo ^a   Takaishi, Hiromasa ^a   Okamoto, Masato ^a,b   Sunamura, Makoto ^e   Kawakami, Yutaka ^a   Kitagawa, Yuko ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KITASATO UNIVERSITY   (Japan)

^c Tokyo Midtown Clinic Health Screening Center   (Japan)

^d KAWASAKI MUNICIPAL HOSPITAL   (Japan)

^e TOKYO MEDICAL UNIVERSITY HACHIOJI MEDICAL CENTER   (Japan)

Author keywords

Delayed type hypersensitivity; Dendritic cell vaccination; First line therapy; Immunotherapy; Neutrophil lymphocyte ratio

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; CANCER VACCINE; DENDRITIC CELL VACCINE; GAMMA INTERFERON; GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; HLA A24 ANTIGEN; INTERLEUKIN 8; PEPTIDE VACCINE; TETRAMER; WT1 PROTEIN; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; IL8 PROTEIN, HUMAN; WT1 PROTEIN, HUMAN;

ABDOMINAL DISTENSION; ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ANUS FISTULA; ARTICLE; ASCITES; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BRAIN INFARCTION; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER IMMUNIZATION; CANCER PATIENT; CANCER PREVENTION; CANCER SURVIVAL; CELLULITIS; CHEMOTHERAPY INDUCED ANEMIA; CHEMOTHERAPY INDUCED EMESIS; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DIARRHEA; DIZZINESS; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DYSGEUSIA; ENZYME LINKED IMMUNOSPOT ASSAY; FATIGUE; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; GLUCOSE INTOLERANCE; HICCUP; HLA TYPING; HUMAN; HYPOALBUMINEMIA; HYPOXIA; IMMUNOLOGICAL MONITORING; INTERSTITIAL PNEUMONIA; INTESTINE OBSTRUCTION; LIVER METASTASIS; MALAISE; MALE; MENSTRUAL IRREGULARITY; MIDDLE AGED; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; NEUTROPHIL LYMPHOCYTE RATIO; OVERALL SURVIVAL; PAIN; PANCREAS CANCER; PERIPHERAL EDEMA; PERITONITIS; PHASE 1 CLINICAL TRIAL; PILOT STUDY; PRIORITY JOURNAL; REPEATED DRUG DOSE; SUPPRESSOR CELL; SURVIVAL RATE; THROMBOCYTOPENIA; URTICARIA; VOMITING; WEIGHT REDUCTION; ADOPTIVE IMMUNOTHERAPY; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; BLOOD; CD8+ T LYMPHOCYTE; CLINICAL TRIAL; DENDRITIC CELL; IMMUNOLOGY; LIVER TUMOR; LYMPHOCYTE COUNT; METABOLISM; MORTALITY; MULTIMODALITY CANCER THERAPY; NEUTROPHIL; PANCREATIC NEOPLASMS; PROCEDURES; SECONDARY; TRANSPLANTATION; TREATMENT OUTCOME; VACCINATION;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; C-REACTIVE PROTEIN; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; COMBINED MODALITY THERAPY; DENDRITIC CELLS; DEOXYCYTIDINE; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-8; LIVER NEOPLASMS; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; NEUTROPHILS; PANCREATIC NEOPLASMS; PILOT PROJECTS; TREATMENT OUTCOME; VACCINATION; WT1 PROTEINS;

EID: 84928057119     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12621     Document Type: Article

References (45)

1. Burris HA 3rd, Moore MJ, Andersen J et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 2403-13.
2. Ueno H, Ioka T, Ikeda M et al. Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J Clin Oncol 2013; 31: 1640-8.
3. Von Hoff DD, Ervin T, Arena FP et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013; 369: 1691-703.
4. Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer 2012; 12: 265-77.
5. Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363: 411-22.
6. Cheever MA, Allison JP, Ferris AS et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 2009; 15: 5323-37.
7. Call KM, Glaser T, Ito CY et al. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell 1990; 60: 509-20.
8. Gashler AL, Bonthron DT, Madden SL et al. Human platelet-derived growth factor A chain is transcriptionally repressed by the Wilms tumor suppressor WT1. Proc Natl Acad Sci U S A 1992; 89: 10984-8.
9. Harrington MA, Konicek B, Song A et al. Inhibition of colony-stimulating factor-1 promoter activity by the product of the Wilms' tumor locus. J Biol Chem 1993; 268: 21271-5.
10. Drummond IA, Madden SL, Rohwer-Nutter P et al. Repression of the insulin-like growth factor II gene by the Wilms tumor suppressor WT1. Science 1992; 257: 674-8.
11. Oji Y, Nakamori S, Fujikawa M et al. Overexpression of the Wilms' tumor gene WT1 in pancreatic ductal adenocarcinoma. Cancer Sci 2004; 95: 583-7.
12. Sugiyama H. Cancer immunotherapy targeting Wilms' tumor gene WT1 product. Expert Rev Vaccines 2005; 4: 503-12.
13. Miyatake T, Ueda Y, Morimoto A et al. WT1 peptide immunotherapy for gynecologic malignancies resistant to conventional therapies: a phase II trial. J Cancer Res Clin Oncol 2013; 139: 457-63.
14. Ohno S, Okuyama R, Aruga A et al. Phase I trial of Wilms' Tumor 1 (WT1) peptide vaccine with GM-CSF or CpG in patients with solid malignancy. Anticancer Res 2012; 32: 2263-9.
15. Tsuboi A, Oka Y, Udaka K et al. Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A*2402-binding residues. Cancer Immunol Immunother 2002; 51: 614-20.
16. Nishida S, Koido S, Takeda Y et al. Wilms tumor gene (WT1) peptide-based cancer vaccine combined with gemcitabine for patients with advanced pancreatic cancer. J Immunother 2014; 37: 105-14.
17. Suzuki E, Kapoor V, Jassar AS et al. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res 2005; 11: 6713-21.
18. Sinha P, Clements VK, Bunt SK et al. Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J Immunol 2007; 179: 977-83.
19. Le HK, Graham L, Cha E et al. Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice. Int Immunopharmacol 2009; 9: 900-9.
20. Soeda A, Morita-Hoshi Y, Makiyama H et al. Regular dose of gemcitabine induces an increase in CD14+ monocytes and CD11c+ dendritic cells in patients with advanced pancreatic cancer. Jpn J Clin Oncol 2009; 39: 797-806.
21. Takahara A, Koido S, Ito M et al. Gemcitabine enhances Wilms' tumor gene WT1 expression and sensitizes human pancreatic cancer cells with WT1-specific T-cell-mediated antitumor immune response. Cancer Immunol Immunother 2011; 60: 1289-97.
22. Kimura Y, Tsukada J, Tomoda T et al. Clinical and immunologic evaluation of dendritic cell-based immunotherapy in combination with gemcitabine and/or S-1 in patients with advanced pancreatic carcinoma. Pancreas 2012; 41: 195-205.
23. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-47.
24. Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ. Dendritic cell immunotherapy: mapping the way. Nat Med 2004; 10: 475-80.
25. Ohnishi M, Sakurai T, Heike Y et al. Evaluation of cytomegalovirus-specific T-cell reconstitution in patients after various allogeneic haematopoietic stem cell transplantation using interferon-gamma-enzyme-linked immunospot and human leucocyte antigen tetramer assays with an immunodominant T-cell epitope. Br J Haematol 2005; 131: 472-9.
26. Kuwana M, Okazaki Y, Kaburaki J, Ikeda Y. Detection of circulating B cells secreting platelet-specific autoantibody is useful in the diagnosis of autoimmune thrombocytopenia. Am J Med 2003; 114: 322-5.
27. Aapro MS, Martin C, Hatty S. Gemcitabine-a safety review. Anticancer Drugs 1998; 9: 191-201.
28. Green MR. Gemcitabine safety overview. Semin Oncol 1996; 23: 32-5.
29. Belknap SM, Kuzel TM, Yarnold PR et al. Clinical features and correlates of gemcitabine-associated lung injury: findings from the RADAR project. Cancer 2006; 106: 2051-7.
30. Kobayashi M, Sakabe T, Abe H et al. Dendritic cell-based immunotherapy targeting synthesized peptides for advanced biliary tract cancer. J Gastrointest Surg 2013; 17: 1609-17.
31. Shirakata T, Oka Y, Nishida S et al. WT1 peptide therapy for a patient with chemotherapy-resistant salivary gland cancer. Anticancer Res 2012; 32: 1081-5.
32. Kaida M, Morita-Hoshi Y, Soeda A et al. Phase 1 trial of Wilms tumor 1 (WT1) peptide vaccine and gemcitabine combination therapy in patients with advanced pancreatic or biliary tract cancer. J Immunother 2011; 34: 92-9.
33. Matsuno O, Okubo T, Hiroshige S et al. Drug-induced lymphocyte stimulation test is not useful for the diagnosis of drug-induced pneumonia. Tohoku J Exp Med 2007; 212: 49-53.
34. Matsuno O. Drug-induced interstitial lung disease: mechanisms and best diagnostic approaches. Respir Res 2012; 13: 39.
35. Stotz M, Gerger A, Eisner F et al. Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer. Br J Cancer 2013; 109: 416-21.
36. Shimizu K, Kotera Y, Aruga A et al. Postoperative dendritic cell vaccine plus activated T-cell transfer improves the survival of patients with invasive hepatocellular carcinoma. Hum Vaccin Immunother 2014; 10: 970-6.
37. Hersey P, Menzies S, Halliday G et al. Phase I/II study of treatment with dendritic cell vaccines in patients with disseminated melanoma. Cancer Immunol Immunother 2004; 53: 125-34.
38. de Vries IJ, Bernsen MR, Lesterhuis WJ et al. Immunomonitoring tumor-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome. J Clin Oncol 2005; 23: 5779-87.
39. Reyes D, Salazar L, Espinoza E et al. Tumour cell lysate-loaded dendritic cell vaccine induces biochemical and memory immune response in castration-resistant prostate cancer patients. Br J Cancer 2013; 109: 1488-97.
40. Rodriguez PC, Ernstoff MS, Hernandez C et al. Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res 2009; 69: 1553-60.
41. Pine JK, Fusai KG, Young R et al. Serum C-reactive protein concentration and the prognosis of ductal adenocarcinoma of the head of pancreas. Eur J Surg Oncol 2009; 35: 605-10.
42. Chen Y, Shi M, Yu GZ et al. Interleukin-8, a promising predictor for prognosis of pancreatic cancer. World J Gastroenterol 2012; 18: 1123-9.
43. Dima SO, Tanase C, Albulescu R et al. An exploratory study of inflammatory cytokines as prognostic biomarkers in patients with ductal pancreatic adenocarcinoma. Pancreas 2012; 41: 1001-7.
44. Mitsunaga S, Ikeda M, Shimizu S et al. Serum levels of IL-6 and IL-1beta can predict the efficacy of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer 2013; 108: 2063-9.
45. Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-23.